Scholarlink

<p>The COVID-19 pandemic accelerated vaccine development and generated a rapidly evolving body of evidence before and after the vaccine rollout. We developed a robust online platform to efficiently synthesize this emerging information for current and future challenges. Expanding upon our interactive living systematic review—initially focused on COVID-19— we now include chikungunya and Lassa fever (with protocols presented in this issue), Mpox, and Disease X (<a href="https://www.safeinpregnancy.org">https://www.safeinpregnancy.org</a>). We aim to continuously monitor and periodically update and disseminate high-quality data on vaccine safety, efficacy, effectiveness, and immunogenicity in pregnancy and childhood. This platform computes real-time meta-analyses and features a visualization tool to present findings in a clear and accessible manner, supporting decision-making, vaccine development pipelines, and implementation strategies worldwide. It is also designed to integrate data on a hub of emerging vaccines in pregnancy and childhood and reflects a collaborative effort among multiple organizations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A global living systematic review and meta-analysis hub of emerging vaccines in pregnancy and childhood

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月18日

查看全文
  • Agustín Ciapponi,
  • Ariel Bardach,
  • Mabel Berrueta,
  • Jamile Ballivian,
  • Martin Brizuela,
  • Julieta Caravario,
  • Noelia Castellana,
  • Daniel Comande,
  • Esteban Couto,
  • Agustina Mazzoni,
  • Vanesa Ortega,
  • Edward P. K. Parker,
  • Juan M. Sambade,
  • Salva Florencia,
  • Juan Pablo Smutny,
  • Katharina Stegelmann,
  • Xu Xiong,
  • Andy Stergachis,
  • Flor M. Munoz,
  • Pierre Buekens

摘要

The COVID-19 pandemic accelerated vaccine development and generated a rapidly evolving body of evidence before and after the vaccine rollout. We developed a robust online platform to efficiently synthesize this emerging information for current and future challenges. Expanding upon our interactive living systematic review—initially focused on COVID-19— we now include chikungunya and Lassa fever (with protocols presented in this issue), Mpox, and Disease X (https://www.safeinpregnancy.org). We aim to continuously monitor and periodically update and disseminate high-quality data on vaccine safety, efficacy, effectiveness, and immunogenicity in pregnancy and childhood. This platform computes real-time meta-analyses and features a visualization tool to present findings in a clear and accessible manner, supporting decision-making, vaccine development pipelines, and implementation strategies worldwide. It is also designed to integrate data on a hub of emerging vaccines in pregnancy and childhood and reflects a collaborative effort among multiple organizations.